Paraquat Poisoning

Disclaimer: This document provides comprehensive medical information for educational and reference purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Clinicians must always exercise their independent medical judgment, consider individual patient circumstances, and consult the latest clinical guidelines and evidence when making patient care decisions. The information provided here should not be used to diagnose or treat a health problem or disease without consulting with a qualified healthcare provider.

Overview

• Definition: Paraquat (1,1'-dimethyl-4,4'-bipyridinium dichloride) is a highly toxic, non-selective bipyridyl herbicide widely used in agriculture. Poisoning occurs most commonly via oral ingestion, leading to severe multi-organ failure, particularly affecting the lungs, kidneys, and liver, often resulting in death.
• Epidemiology:
  • Globally, paraquat poisoning is a significant cause of fatal poisoning, particularly in developing countries, where it is readily available and often used in suicide attempts.
  • Prevalence varies by region, with high rates in Asia (e.g., China, Korea, Sri Lanka, Taiwan) and parts of South America.
  • Accidental poisoning can occur, but intentional self-harm is the predominant mode of exposure.
  • Occupational exposure (dermal or inhalation) is less common but can occur, typically leading to milder symptoms unless exposure is prolonged or extensive.
• Classification:
  • Acute Severe Poisoning: Ingestion of a large amount (e.g., >40 mg/kg or >50 mL of 20% solution). Characterized by rapid onset of multi-organ failure (renal, hepatic, cardiac, respiratory, CNS) within hours to days, often leading to death despite aggressive treatment.
  • Acute Moderate Poisoning: Ingestion of a moderate amount (e.g., 20-40 mg/kg or 20-50 mL of 20% solution). Gastrointestinal symptoms followed by kidney and liver dysfunction, and later, progressive pulmonary fibrosis. High mortality rate.
  • Acute Mild Poisoning: Ingestion of a small amount (e.g., <20 mg/kg or <20 mL of 20% solution). Primarily gastrointestinal symptoms, possible mild renal impairment, and less severe or delayed pulmonary fibrosis. Better prognosis, but still requires vigilant monitoring.
  • Dermal/Inhalation Exposure: Less common, usually localized skin irritation or mild respiratory symptoms unless exposure is massive or prolonged.

Pathophysiology

• Mechanism: Paraquat's toxicity stems primarily from its ability to undergo redox cycling within cells.
  1. Reduction: Paraquat is readily reduced by NADPH-cytochrome P450 reductase to form a paraquat free radical.
  2. Oxidation: This paraquat radical rapidly reacts with molecular oxygen (O2) to regenerate parent paraquat and produce superoxide anion (O2•-), a highly reactive oxygen species (ROS).
  3. Chain Reaction: This cycle consumes NADPH, depletes cellular reducing equivalents, and generates large amounts of ROS (superoxide, hydrogen peroxide, hydroxyl radicals).
  4. Oxidative Stress: The excessive ROS overwhelm the cell's antioxidant defense mechanisms (e.g., superoxide dismutase, catalase, glutathione reductase), leading to severe oxidative stress.
  5. Cellular Damage: Oxidative stress causes lipid peroxidation of cell membranes, protein denaturation, DNA damage, and mitochondrial dysfunction, ultimately leading to cellular necrosis and apoptosis. * Organ Specificity: Paraquat is actively transported into type I and type II alveolar epithelial cells in the lungs via polyamine transport systems, leading to high concentrations and severe pulmonary damage (alveolitis, edema, hemorrhage, and ultimately irreversible pulmonary fibrosis). It is also concentrated in the kidneys (leading to acute tubular necrosis) and to a lesser extent, the liver, heart, and CNS.
• Risk Factors:
  • Availability: Easy access to paraquat (e.g., in agricultural regions).
  • Mental Health Issues: Depression, suicidal ideation.
  • Lack of Regulation: Insufficient restrictions on sale and use.
  • Poor Storage Practices: Unsecured storage of the herbicide.
• Protective Factors:
  • Strict Regulations: Banning or restricting the sale of paraquat to authorized users.
  • Addition of Adjuvants: Inclusion of emetics, dyes, and strong odors in paraquat formulations to deter accidental or intentional ingestion.
  • Public Awareness: Education campaigns on the dangers of paraquat.
  • Early Medical Intervention: Rapid access to emergency medical care and decontamination.

Clinical Presentation

Signs and Symptoms

• Cardinal Features: Multi-organ failure, especially progressive pulmonary fibrosis leading to respiratory failure, and acute kidney injury.
• Early Signs (within hours to days):
  • Gastrointestinal: Corrosive injury to the mouth, pharynx, esophagus, and stomach. Oral pain, burning sensation, odynophagia, dysphagia, nausea, vomiting, epigastric pain, diarrhea (often bloody). Pseudomembrane formation or ulcerations in the oral cavity and pharynx are highly characteristic.
  • Renal: Oliguria, anuria, flank pain due as acute tubular necrosis develops.
  • Hepatic: Jaundice, right upper quadrant pain as liver injury progresses (elevated transaminases, bilirubin).
  • Cardiovascular: Tachycardia, hypotension, arrhythmias.
  • Respiratory: Cough, dyspnea.
• Advanced Signs (days to weeks):
  • Pulmonary: Progressive dyspnea, tachypnea, cyanosis, acute respiratory distress syndrome (ARDS), leading to irreversible pulmonary fibrosis (the most common cause of death in survivors of the acute phase).
  • Renal: Worsening acute kidney injury requiring dialysis.
  • Hepatic: Fulminant hepatic failure.
  • Central Nervous System: Tremors, seizures, confusion, coma (especially in severe cases).
  • Adrenal: Adrenal necrosis.
  • Multi-organ Failure: Progressive deterioration of multiple organ systems.
• Atypical Presentations:
  • Dermal Exposure: Localized skin irritation, blisters, chemical burns.
  • Inhalation Exposure: Nasal irritation, epistaxis, sore throat, cough, chest tightness; severe cases can lead to pulmonary edema and fibrosis.
  • Ocular Exposure: Conjunctivitis, corneal ulceration, globe rupture.

Physical Examination

• Inspection:
  • Oral Cavity: Oral ulcers, erosions, pseudomembranes, white patches on the tongue, gums, buccal mucosa, or pharynx (highly suggestive of paraquat ingestion).
  • Skin: Dermal burns, blisters, discoloration (from dye in the formulation).
  • Respiratory: Tachypnea, accessory muscle use, signs of respiratory distress, cyanosis.
  • General: Jaundice, anasarca, altered mental status.
• Palpation:
  • Abdomen: Epigastric tenderness, right upper quadrant tenderness.
  • Lungs: Crepitations, rhonchi (indicating pulmonary edema/fibrosis).
• Special Tests: No specific "special tests" in the traditional sense, but focused examination of oral cavity and respiratory system is paramount.

Diagnostic Approach

History Taking

• Key Questions:
  • Substance: What substance was ingested? (crucial to obtain the container/label).
  • Amount: Estimated amount ingested.
  • Time: Time of ingestion.
  • Co-ingestants: Any other substances ingested?
  • Route: Route of exposure (oral, dermal, inhalation).
  • Circumstances: Intentional (suicidal attempt) vs. accidental.
  • Symptom Onset: When did symptoms begin and how have they progressed?
  • Prior Illnesses: Pre-existing renal, hepatic, or pulmonary disease.
• Red Flags:
  • Known or suspected ingestion of paraquat.
  • Oral ulcerations/burns, dysphagia.
  • Rapid onset of gastrointestinal symptoms (nausea, vomiting, abdominal pain).
  • Oliguria/anuria.
  • Progressive dyspnea.
  • Deteriorating mental status.

Laboratory Tests

• First-Line:
  • Urine Paraquat Test: Rapid qualitative screening using dithionite reduction test. A blue color change indicates presence of paraquat. Positive test should prompt aggressive treatment. A negative test within a few hours of ingestion makes significant exposure unlikely.
  • Blood Paraquat Level: Quantitative plasma paraquat concentration is crucial for prognosis and guiding management. Samples should be collected immediately upon presentation and at regular intervals. Levels >0.2 mg/L at 24 hours, >0.1 mg/L at 48 hours, or >0.05 mg/L at 72 hours are associated with poor prognosis.
  • Complete Blood Count (CBC): To check for leukocytosis, anemia.
  • Basic Metabolic Panel (BMP): Urea, creatinine, electrolytes (especially potassium, sodium, bicarbonate) for renal function and acid-base status.
  • Liver Function Tests (LFTs): ALT, AST, alkaline phosphatase, bilirubin for hepatic injury.
  • Arterial Blood Gas (ABG): To assess oxygenation and acid-base status (metabolic acidosis is common).
  • Urinalysis: To assess for renal tubular damage (proteinuria, hematuria).
  • Blood Glucose: Hypoglycemia or hyperglycemia can occur.
• Confirmatory:
  • Quantitative Plasma Paraquat Levels: Gold standard for diagnosis and prognosis. Specific assays (e.g., HPLC, GC-MS) are needed.
• Monitoring:
  • Repeat CBC, BMP, LFTs, ABG daily or more frequently depending on clinical status.
  • Daily urine output monitoring.
  • Serial plasma paraquat levels to assess elimination, if possible.
  • Follow-up chest X-rays.

Imaging

• Recommended:
  • Chest X-ray (CXR): Initially may be normal. Later, signs of pulmonary edema, infiltrates, or diffuse interstitial changes, progressing to reticular or reticulonodular patterns consistent with fibrosis.
• Advanced:
  • High-Resolution Computed Tomography (HRCT) of the Chest: More sensitive for detecting early interstitial lung disease, ground-glass opacities, consolidation, and progression to fibrosis. Crucial for assessing lung involvement and prognosis.
  • Abdominal Ultrasound/CT: To assess for bowel wall thickening, perforation, or other signs of gastrointestinal corrosive injury, and to evaluate renal or hepatic involvement if clinical signs warrant.

Management

Note: There is no specific antidote for paraquat poisoning. Management focuses on preventing absorption, enhancing elimination, mitigating oxidative damage, and providing aggressive supportive care. Early and aggressive intervention is crucial for improving outcomes.

Acute Management

• Immediate (within minutes to 1-2 hours of ingestion):
  • Stabilization: Assess ABCs (Airway, Breathing, Circulation). Ensure patent airway, provide oxygen if needed (with caution – see below), establish IV access, and initiate fluid resuscitation for hypotension if present.
  • Gastric Decontamination:
    • Gastric Lavage: If ingestion is recent (within 1-2 hours) and the amount is significant. Use a large bore orogastric tube and isotonic saline. Protect airway (intubate if altered mental status or risk of aspiration).
    • Activated Charcoal: Administer 1 g/kg (max 50-100 g) orally or via NG tube, ideally within 1-2 hours of ingestion. Repeat doses are not generally recommended due to limited evidence of benefit and risk of aspiration.
    • Adsorbent Clays: Fuller's earth (hydrated attapulgite) or bentonite (hydrated aluminum silicate) are highly effective in adsorbing paraquat in the gut and are preferred over activated charcoal if available.
      • Fuller's Earth: 100-150 g in 200 mL water (adults), 2 g/kg in water (children), orally or via NG tube. Repeat every 2-4 hours for 24-48 hours.
      • Bentonite: Similar dosing as Fuller's earth.
  • Cathartics: Not routinely recommended. Sorbitol or magnesium citrate are sometimes used with activated charcoal, but risk of fluid shifts and electrolyte disturbances.
  • Induce Vomiting (e.g., with ipecac): CONTRAINDICATED due to the corrosive nature of paraquat and risk of worsening GI tract injury and aspiration.
• Stabilization (early management priorities):
  • Fluid and Electrolyte Management: Correct dehydration and electrolyte imbalances, monitor urine output.
  • Renal Replacement Therapy (RRT):
    • Hemoperfusion (HP): Most effective method for enhancing paraquat elimination from blood, especially if initiated early.
      • Indications: Recommended for moderate to severe poisoning, especially if initiated within 4-6 hours (some recommend up to 12-24 hours post-ingestion, particularly for patients with good initial GCS and renal function).
      • Frequency: Typically daily or twice daily for 2-3 days, depending on plasma levels and clinical status.
      • Paraquat Clearance: HP clears paraquat effectively, especially from the central compartment, but does not effectively remove paraquat from tissues.
    • Hemodialysis (HD): Less effective than hemoperfusion but can be used for renal failure. Combination of HP and HD may be considered.
• Emergency (Crisis management):
  • Respiratory Support:
    • Avoid High FiO2: This is a critical point. Oxygen therapy can exacerbate lung injury by increasing the formation of ROS in paraquat-laden lung cells. Use the lowest possible FiO2 to maintain adequate oxygen saturation (e.g., aiming for SpO2 88-92% if tolerated) unless severe hypoxemia is life-threatening and cannot be managed otherwise. If intubation and mechanical ventilation are required, aim for lung-protective ventilation strategies with low tidal volumes.
  • Immunosuppression: Controversial but commonly used in moderate-to-severe cases, aiming to reduce inflammation and fibrosis. Evidence from clinical trials is mixed, but some studies suggest benefit, especially when initiated early.
    • Corticosteroids: Methylprednisolone 1 g IV daily for 3 days, followed by tapering doses. Or Dexamethasone 10-20 mg IV daily.
    • Cyclophosphamide: 15 mg/kg IV daily for 2 days followed by 10 mg/kg IV on day 3 (or 1 g IV daily for 3 days). Often combined with corticosteroids. Monitor for myelosuppression and hemorrhagic cystitis.
    • Mycophenolate Mofetil: Some studies suggest benefit.
  • Antioxidants/Other Adjuncts: Limited evidence, but often used:
    • N-acetylcysteine (NAC): 150 mg/kg IV over 15 min, then 50 mg/kg IV over 4 hours, then 100 mg/kg IV over 16 hours. Or 140 mg/kg orally, followed by 70 mg/kg every 4 hours for 17 doses. May replenish glutathione stores.
    • Vitamin C (Ascorbic Acid): High doses (e.g., 2 g IV every 6 hours) are sometimes used as an antioxidant.
    • Vitamin E: Antioxidant.
    • Deferoxamine: Iron chelator, can theoretically reduce hydroxyl radical formation.
    • Propranolol: May reduce paraquat uptake into lung cells, but not routinely recommended.
  • Pain Management: Opioids for severe pain from corrosive injury.
  • Nutritional Support: Early enteral or parenteral nutrition, especially if severe GI injury.

Chronic Management

• Pharmacological:
  • Corticosteroids/Immunosuppressants: For ongoing inflammation or progressive fibrosis, but effectiveness significantly decreases once fibrosis is established.
  • Anti-fibrotic Agents: Agents like pirfenidone or nintedanib (used for idiopathic pulmonary fibrosis) have been explored but their role in paraquat-induced lung fibrosis is not well-established and generally not recommended.
• Non-pharmacological:
  • Pulmonary Rehabilitation: For patients with residual lung function impairment.
  • Psychological Support: For patients with long-term complications and for managing the underlying psychiatric issues (if intentional poisoning).
  • Nutrition: Ongoing nutritional support.
  • Lung Transplantation: A potential option for end-stage pulmonary fibrosis, but highly complex and rarely feasible given the severe multi-organ involvement and underlying psychiatric issues.
• Monitoring:
  • Pulmonary Function Tests (PFTs): To assess lung function periodically.
  • Serial HRCT Chest Scans: To monitor progression or stability of lung fibrosis.
  • Renal Function: Long-term monitoring for chronic kidney disease.
  • Liver Function: Long-term monitoring for chronic liver disease.
  • Psychiatric Evaluation: For ongoing mental health support.

Treatment Algorithms

• First-Line (Immediate & Early):
  1. ABC Stabilization.
  2. Gastric Decontamination: Fuller's earth/bentonite or activated charcoal + gastric lavage (if within 1-2h).
  3. Enhanced Elimination: Hemoperfusion (HP) as early as possible for moderate-to-severe cases (ideally within 4-6 hours, up to 12-24 hours depending on clinical picture).
  4. Supportive Care: Fluid/electrolyte balance, aggressive monitoring of organ function.
  5. Caution with Oxygen: Limit FiO2 unless critically hypoxic.
  6. Consider Immunosuppression: Methylprednisolone + Cyclophosphamide (early initiation).
• Second-Line (Adjunctive & Ongoing):
  1. Antioxidants: NAC, Vitamin C/E (though evidence for benefit is limited).
  2. Repeated HP: If initial levels are very high or clinical deterioration.
  3. Renal Replacement Therapy: If acute kidney injury progresses to failure.
• Refractory Cases:
  • When multi-organ failure progresses despite aggressive measures, management becomes palliative.
  • For end-stage pulmonary fibrosis, lung transplantation might be considered in very select cases, but is highly challenging due to the systemic nature of the poisoning and high mortality.

Complications

• Common:
  • Gastrointestinal: Esophagitis, gastritis, peptic ulcers, pseudomembrane formation, esophageal strictures, stomatitis, enteritis, paralytic ileus.
  • Renal: Acute tubular necrosis, acute kidney injury, chronic kidney disease.
  • Hepatic: Hepatocellular injury, elevated transaminases, jaundice, hepatic failure.
  • Respiratory: Alveolitis, pulmonary edema, ARDS, progressive pulmonary fibrosis.
• Serious:
  • Respiratory Failure: Due to ARDS and irreversible pulmonary fibrosis, the most common cause of death.
  • Multi-organ Failure: Combined renal, hepatic, cardiac, and respiratory failure.
  • Cardiac Dysfunction: Myocarditis, arrhythmias, heart failure.
  • Central Nervous System: Seizures, encephalopathy, coma.
  • Adrenal Necrosis: Adrenal insufficiency.
  • Systemic Inflammatory Response Syndrome (SIRS) / Sepsis: From mucosal damage and immunosuppression.
• Long-term:
  • Chronic Pulmonary Fibrosis: Persistent dyspnea, reduced lung function, requiring supplemental oxygen.
  • Esophageal Strictures: Requiring dilatation.
  • Chronic Kidney Disease.
  • Psychological Sequelae: Depression, anxiety, PTSD.

Prognosis

• Factors:
  • Amount Ingested: The single most important prognostic factor. Even small amounts can be fatal.
  • Plasma Paraquat Concentration: Directly correlates with severity and mortality. Levels >2 mg/L at 6 hours, >0.2 mg/L at 24 hours, or >0.1 mg/L at 48 hours are associated with very high mortality (>80%).
  • Time to Presentation/Treatment: Earlier presentation and aggressive decontamination/elimination improve prognosis.
  • Clinical Features: Onset of oliguria, severe GI symptoms, ARDS, altered mental status, and a low Glasgow Coma Scale (GCS) score are indicators of poor prognosis.
  • Kidney Function: Deteriorating renal function is a poor prognostic sign.
  • Oxygen Use: Inappropriate high-dose oxygen therapy worsens lung injury and prognosis.
• Survival:
  • Overall mortality rate is extremely high, ranging from 50% to 90%, particularly in severe ingestions.
  • Survival rates are better for small ingestions or if rapid and effective early intervention (especially hemoperfusion) is performed.
• Quality of Life:
  • Survivors often suffer from significant long-term complications, predominantly chronic pulmonary fibrosis, which can severely impair quality of life due to persistent dyspnea and exercise intolerance.
  • Chronic kidney or liver disease may also contribute to morbidity.
  • Psychological burden is significant for survivors and their families.

Prevention

• Primary (Preventing initial occurrence):
  • Restrict Access: Strict regulation or complete ban of paraquat use (several countries have banned it).
  • Additives: Incorporation of strong emetics (e.g., diquat), foul odors, and blue dyes into paraquat formulations to deter accidental or intentional ingestion.
  • Public Education: Campaigns on the dangers of paraquat and safe handling practices.
  • Secure Storage: Promote secure storage of herbicides in agricultural settings.
• Secondary (Early detection and intervention):
  • Rapid Referral: Prompt transfer of suspected cases to well-equipped medical facilities.
  • Early Diagnosis: Emphasize the importance of early urine and blood paraquat level testing.
  • Aggressive Decontamination: Immediate gastric lavage and administration of adsorbents upon presentation.
• Tertiary (Preventing complications):
  • Aggressive Supportive Care: To minimize organ damage.
  • Immunosuppression and Enhanced Elimination: Timely initiation of these therapies in appropriate cases.
  • Long-term Follow-up: For management of chronic sequelae.

Special Populations

• Pediatric:
  • Children may accidentally ingest paraquat, especially if stored improperly.
  • Paraquat poisoning in children is often more severe relative to body weight due to higher metabolic rates and less developed physiological reserves.
  • Management principles are similar but require careful dose adjustments for medications and fluid management.
• Geriatric:
  • Elderly patients may have underlying comorbidities (e.g., renal impairment, cardiovascular disease) that can complicate paraquat poisoning and its management.
  • Increased susceptibility to drug toxicities and fluid/electrolyte disturbances.
  • Prognosis may be worse due to frailty and reduced physiological reserve.
• Pregnancy:
  • Paraquat is highly toxic to both the mother and fetus.
  • Can cause fetal death, malformations, and premature birth.
  • Management prioritizes maternal stabilization, but fetal viability must also be considered.
  • Specific considerations for drug choices (e.g., cyclophosphamide is teratogenic) and potential for fetal exposure during procedures like hemoperfusion.
• Comorbidities:
  • Pre-existing Renal Disease: Worsens prognosis due to impaired excretion and increased susceptibility to acute kidney injury. Hemoperfusion is even more critical.
  • Pre-existing Pulmonary Disease: Patients with COPD, asthma, or other lung conditions are at higher risk for severe respiratory compromise.
  • Cardiac Disease: Increased risk of arrhythmias and heart failure.
  • Immunocompromised Patients: Higher risk of infections, may influence immunosuppressive therapy choices.

Clinical Pearls

• Diagnostic:
  • "Paraquat mouth": Oral ulcerations, erosions, or pseudomembranes are highly characteristic and should immediately raise suspicion of paraquat ingestion.
  • Urine Dithionite Test: A simple, rapid bedside test for screening. A positive result (blue color) confirms paraquat presence and mandates immediate aggressive management.
  • Plasma Level is King: Quantitative plasma paraquat level is the most critical prognostic indicator. Obtain it early and repeat for monitoring.
• Treatment:
  • Time is Tissue: Early decontamination and enhanced elimination (especially hemoperfusion) are paramount. The window of opportunity is narrow.
  • No Antidote: Emphasize that there is no specific antidote; treatment is largely supportive and aimed at limiting absorption and enhancing elimination.
  • Oxygen is a Double-Edged Sword: Judicious oxygen use is critical. Avoid high FiO2 unless absolutely necessary to prevent severe hypoxemia, as it can worsen lung injury.
  • Immunosuppression: While controversial, combining methylprednisolone and cyclophosphamide early is a common strategy in moderate-to-severe cases.
  • Aggressive Hydration: Maintain good urine output to aid renal excretion and prevent renal injury, but avoid fluid overload.
• Pitfalls:
  • Delay in Diagnosis: Mistaking early symptoms for gastroenteritis can delay life-saving interventions.
  • Inadequate Decontamination: Not performing gastric lavage or using insufficient amounts of adsorbents.
  • Over-Oxygenation: Providing high FiO2 empirically, which can accelerate pulmonary fibrosis.
  • Sole Reliance on Dialysis: Hemodialysis alone is insufficient for effective paraquat removal from the blood; hemoperfusion is superior.
  • Underestimation of Severity: Even seemingly small ingestions can be fatal.
  • Ignoring Mental Health: Failing to address underlying suicidal ideation or psychiatric conditions.

Recent Updates

• Guidelines: Ongoing updates emphasize early combined immunosuppression with hemoperfusion for severe cases, but no universally accepted definitive guidelines across all regions due to variations in local availability and clinical practices. Some national guidelines now include specific protocols for these combinations.
• Evidence:
  • Research continues into novel anti-fibrotic agents and targeted therapies to prevent lung damage.
  • Studies are exploring the efficacy of new types of adsorbents and more efficient hemoperfusion techniques.
  • Genetic susceptibility to paraquat toxicity is an area of ongoing research.
• Controversies:
  • Role of Immunosuppression: Debate continues regarding the optimal regimen, timing, and patient selection criteria for corticosteroids and cyclophosphamide. Some studies show benefit, others do not, contributing to clinical equipoise.
  • Effectiveness of Antioxidants: While biologically plausible, robust clinical trial data supporting significant benefit from antioxidant therapies (e.g., NAC, Vitamin C/E) in improving outcomes are still lacking.
  • Role of Lung Transplantation: Still highly debated due to the systemic nature of paraquat toxicity and ethical considerations for intentional poisoning cases.

Key References

• Guidelines:
  • Clinical guidelines from major toxicology societies (e.g., American Academy of Clinical Toxicology, European Association of Poisons Centres and Clinical Toxicologists).
  • National poisoning treatment protocols (e.g., Korean, Chinese, Sri Lankan guidelines given high incidence).
• Studies:
  • Landmark clinical trials evaluating hemoperfusion, immunosuppression, and other adjunctive therapies in paraquat poisoning.
  • Retrospective cohort studies and meta-analyses on prognostic factors and treatment outcomes.
• Reviews:
  • Comprehensive reviews in leading toxicology and critical care journals (e.g., Clinical Toxicology, Intensive Care Medicine) summarizing current evidence and management strategies.